127P Phase I study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC. (December 2022) - Cho, B.C.; Dy, G.; Kim, T.M.; Sarker, D.; Hamid, O.; Williamson, S.; Sang-We, K.; Hatim, H.; Chen, S.; Mani, J.; Jankovic, V.; Paccaly, A.J.; et al.